Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 19/20 | 0.41 |
| ▸ | JAK1 | P23458 | 8/20 | 0.41 |
| ▸ | AXL | P30530 | 1/20 | 0.40 |
| ▸ | MERTK | Q12866 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9927012 | 1.00 | JAK2 (0.41) | JAK2JAK1AXLMERTK | |
| SCHEMBL6127635 | 0.94 | AXL (0.46) | JAK2JAK1AXLMERTK | |
| SCHEMBL6126629 | 0.94 | AXL (0.46) | JAK2JAK1AXLMERTK | |
| SCHEMBL6126628 | 0.94 | AXL (0.46) | JAK2JAK1AXLMERTK | |
| SCHEMBL16348662 | 0.91 | AXL (0.44) | JAK2JAK1AXLMERTK | |
| SCHEMBL16348657 | 0.91 | AXL (0.44) | JAK2JAK1AXLMERTK | |
| SCHEMBL29540339 | 0.90 | JAK2 (0.42) | JAK2JAK1 | |
| SCHEMBL20713907 | 0.90 | JAK2 (0.42) | JAK2JAK1 | |
| SCHEMBL22730937 | 0.90 | JAK2 (0.40) | JAK2JAK1AXLMERTK | |
| SCHEMBL28413128 | 0.90 | JAK2 (0.40) | JAK2JAK1AXLMERTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149681-A1 | CYCLOBUTYL SUBSTITUTED PYRROLOPYRIDINE AND PYRROLOPYRIMIDINE DERIVATIVES AS JAK INHIBITORS | INCYTE CORPORATION | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149681-A1 | CYCLOBUTYL SUBSTITUTED PYRROLOPYRIDINE AND PYRROLOPYRIMIDINE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK2, JAK3 | JAK2 2/4885JAK1 1/4885AXL 781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.